Form 4: Illumina Director Caroline Dorsa Granted 3,780 Restricted Stock Units

Illumina, Inc. Director Caroline Dorsa received a grant of 3,780 restricted stock units (RSUs), increasing her beneficial ownership in the company.

Summary

• Caroline Dorsa, a Director of Illumina, Inc. (ILMN), was granted 3,780 shares of common stock in the form of restricted stock units (RSUs) on May 21, 2025.
• The transaction was an acquisition (A) of securities at a price of $0 per share, which is typical for RSU grants.
• Following this transaction, Caroline Dorsa's direct beneficial ownership of Illumina common stock increased to 15,194 shares.
• The restricted stock units are subject to a vesting schedule where 100% of the shares will vest on the earlier of (i) the one-year anniversary of the grant date or (ii) the date immediately preceding the company's annual meeting of stockholders for the year following the grant year.
• Vesting is contingent upon Caroline Dorsa's continued service as a director on the respective vesting date.

Sentiment

Score: 7

Explanation: The document reports a standard, expected insider transaction (RSU grant to a director). This is a neutral to slightly positive event as it aligns the director's interests with shareholders, but it does not indicate any significant operational or financial news.

Positives

• The grant of restricted stock units aligns the director's interests with those of the shareholders, as the value of the compensation is tied to the company's stock performance.
• This transaction represents a standard form of non-cash compensation for directors, indicating continued commitment and engagement from the board member.

Future Outlook

The vesting schedule for the restricted stock units indicates a future commitment from Director Caroline Dorsa to continue serving on Illumina's board for at least one year or until the next annual meeting, aligning her long-term interests with the company's performance.

Industry Context

The grant of restricted stock units to a director is a common practice in the biotechnology and life sciences industry, as well as across publicly traded companies, to compensate board members and align their incentives with long-term shareholder value creation. This type of compensation is a standard component of corporate governance and executive/director remuneration packages.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as a form of director compensation is a widely adopted practice across industries, including the biotechnology sector where Illumina operates.
• Companies like Thermo Fisher Scientific (TMO), Danaher Corporation (DHR), and Agilent Technologies (A) also commonly utilize equity-based compensation, such as RSUs or stock options, for their non-employee directors to foster alignment with shareholder interests and promote long-term commitment.
• The vesting schedule, typically over one year or tied to the next annual meeting, is standard for director RSU grants, ensuring continued service and oversight.

Corporate Governance

Related Party Transactions

• The grant of restricted stock units to Caroline Dorsa, a director of Illumina, Inc., constitutes a related party transaction as it involves compensation provided by the company to an insider.

Stakeholder Impact

• Shareholders: The grant represents a form of equity compensation, which is a standard practice and aligns the director's interests with shareholder value. It involves a minor increase in potential future share count upon vesting, which is typical for equity compensation plans.
• Employees: No direct impact on employees mentioned in this filing.
• Directors: Positive impact for Caroline Dorsa as it represents compensation for her service and increases her beneficial ownership in the company.

Next Steps

• Vesting of the 3,780 restricted stock units on the earlier of the one-year anniversary of the grant date (May 21, 2026) or the date immediately preceding the company's annual meeting of stockholders for the year following the grant, contingent on continued service.

Key Dates

Keywords

Illumina, ILMN, Form 4, Insider Transaction, Restricted Stock Units, RSU, Director Compensation, Stock Grant, Beneficial Ownership